National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 70 years. - A Pilot Study of the Administration of Young Tumor Infiltrating Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen in Metastatic Melanoma.
National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 66 years. - A Phase I/II Study of IL-15 Administration Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen and Autologous Lymphocyte Transfer in Metastatic Melanoma.
National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 66 years. - Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI).
Aldesleukin; Cyclophosphamide; Fludarabine; Young Tumor Infiltrating Lymphocytes; 1200 Gy Irradiation
H. Lee Moffitt Cancer Center and Research Institute - Recruiting 16 years or older. - A Pilot Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51 VG With Escalating Doses of Anti-PD-1 Antibody BMS-936558 for Patients With Unresectable Stages III/IV Melanoma.
MART-1; NY-ESO-1; gp100:209-217(210M); gp100:280-288(288V); Montanide ISA 51 VG; BMS-936558
Assistance Publique - Hpitaux de Paris - Recruiting 18 years or older. - Phase II Multicentric Uncontrolled National Trial Assessing the Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas , Stage III Unresectable Melanomas, or Stage IV Melanomas With c-KIT Mutation or Amplification..